Aortic Valve Stenosis
Q&A: Novel drug may replace ‘watchful waiting’ approach to aortic stenosis care
A novel therapeutic showed significant promise in slowing aortic valve calcification, potentially extending time until or eliminating need for transcatheter or surgical intervention for stenosis, researchers reported.
Lack of Lp(a) screening a ‘missed opportunity’; promising therapies on the horizon
Improved screening for elevated lipoprotein(a) levels among all adults may improve CVD risk assessment and outcomes, especially with multiple Lp(a)-lowering therapies currently in the research pipeline, a speaker reported.
FDA grants breakthrough device designation to AI-powered aortic stenosis screening tool
AccurKardia announced its AI-powered, ECG-based aortic valve stenosis screening software has been granted breakthrough device designation by the FDA.
Real-world 30-day data show noninferiority of new TAVR valve vs. other contemporary valves
A new prosthetic aortic valve with a wider range of intermediate sizing was noninferior at 30 days vs. other contemporary transcatheter aortic valves, a speaker reported.
In small aortic annuli, self-expanding TAVR valve may be preferred for hemodynamics
ATLANTA — In patients with severe aortic stenosis and a small aortic annulus undergoing transcatheter aortic valve replacement, hemodynamic parameters were best with a self-expanding valve, according to data from the SMART trial.
Next-generation TAVR valve linked to less paravalvular leak vs. predecessors
The fifth generation of a balloon-expandable transcatheter aortic valve replacement system was associated with lower rates of paravalvular leak and lower mean gradients compared with predecessor systems, researchers reported.
Minimally symptomatic patients likely to survive with good health status after TAVR
Patients with minimally symptomatic status who underwent transcatheter aortic valve replacement were more likely to survive with good health status at 1 year than more symptomatic patients, researchers reported.
At 10 years, valve dysfunction, deterioration less common with TAVR vs. surgery
After 10 years of follow-up, a self-expanding transcatheter aortic valve replacement system was linked to lower rates of valve dysfunction and deterioration compared with surgical valves in low-risk patients, researchers reported.
Survey: Next-generation TAVR system improves resistance, tracking, ease of alignment
Findings from a survey of operators who used a next-generation transcatheter aortic valve replacement system indicated improved deployment and commissural alignment vs. the device’s predecessor system, a speaker reported.
Primary TAVR may be best strategy for aortic stenosis causing cardiogenic shock
Data suggest transcatheter aortic valve replacement with a balloon-expandable valve is an acceptable and safe treatment for patients with aortic stenosis and cardiogenic shock, researchers reported.